Since April 28, 2026, when the first autologous NK cell therapy procedure for solid tumors was successfully completed at West China Lecheng Hospital, patient interest has grown steadily. The therapy has been formally approved for implementation within the Boao Lecheng International Medical Pilot Zone, with procedures conducted at West China Lecheng Hospital and Lecheng Maisel International Hospital. As a service coordinator based in Lecheng, I have been assisting patients and their families in understanding this new option. This article compiles objective information from regulatory documents, hospital materials, and clinical data—including a balanced discussion of both the therapy’s potential and its inherent limitations.
What Is Autologous NK Cell Therapy?
Natural killer (NK) cells are a subset of lymphocytes that serve as a key component of the innate immune system. They are capable of recognizing and eliminating malignant cells, virus-infected cells, and other abnormal targets without prior sensitization. In the context of oncology, NK cells provide immune surveillance against residual tumor cells that may persist after surgery, radiotherapy, or chemotherapy.
The autologous NK cell therapy protocol involves collecting peripheral blood from the patient, isolating NK cells, expanding them ex vivo to a quantity of 1 to 3 billion cells, and then reinfusing them intravenously. The core principle is “取之于己、用之于己” (from the patient, for the patient), which minimizes the risk of immune rejection.
The therapy is typically combined with PD-1 immune checkpoint inhibitors. The rationale is well established: PD-1 blockade not only restores T-cell activity but also enhances NK cell function by blocking PD-1/PD-L1 inhibitory signals on NK cells, augmenting antibody-dependent cell-mediated cytotoxicity (ADCC), inducing NK cell phenotypic conversion, and indirectly reversing NK cell exhaustion through effects on CD8+ T cells and Tregs.
Mechanisms of Action
NK cells employ multiple mechanisms to eliminate tumor cells:
When combined with PD-1 inhibitors, the synergistic effect is particularly notable: PD-1 blockade enhances NK cell anti-tumor activity, increases the number of circulating NK cells, and improves the overall immune response against the tumor.
Clinical Evidence: Efficacy Data
The NK cell therapy program has accumulated clinical experience from over a thousand patients with solid tumors. The published data demonstrate both safety and efficacy, with documented improvements in treatment tolerance, quality of life, and survival outcomes.
Specific data from non-small cell lung cancer (NSCLC) studies illustrate the magnitude of the effect:
- NK + PD-1 vs. PD-1 alone: In a study of advanced NSCLC, the combination therapy group achieved an objective response rate (ORR) of 41.7% vs. 0% in the monotherapy group, and a 1-year survival rate of 66.7% vs. 50.0%. Median progression-free survival (PFS) was 6.2 months vs. 1.6 months.
- NK + Sintilimab in platinum-resistant NSCLC: In patients with IIIB/IIIC or stage IV NSCLC who had failed first-line platinum-based chemotherapy, the combination achieved a median PFS of 11.6 months, an ORR of 45%, and a median overall survival (OS) of 17.7 months over a median follow-up of 22.6 months.
- 2-year survival benefit: In another study of autologous NK cells combined with pembrolizumab, the 2-year survival rate was 58.3% in the combination group vs. 16.7% in the control group.
Understanding the Limitations: Three Realistic Shortcomings
While the clinical data are encouraging, it is equally important to understand what NK cell therapy cannot achieve. As one analysis notes, NK cell therapy “is useful, but by no means a panacea”. The therapy has three inherent limitations that directly affect its efficacy ceiling:
① Difficulty penetrating solid tumor cores
NK cells are highly effective at eliminating circulating tumor cells and micrometastases in the bloodstream. However, once a solid tumor has formed and matured, the situation changes dramatically. Solid tumors have dense, fibrotic internal structures that act like fortified fortresses. Large numbers of infused NK cells tend to accumulate at the tumor periphery, with only a small fraction able to penetrate the core. The result is often a “siege without assault” — for large, established tumors, direct killing is difficult to achieve. This is a general bottleneck in adoptive cell therapy, not a problem that can be solved simply by increasing the cell dose.
② Re-suppression within the tumor microenvironment
Even if some NK cells successfully infiltrate the tumor tissue, they encounter the same hostile conditions that disabled the patient’s own immune cells. Hypoxia, acidic pH, and a dense network of immunosuppressive cytokines rapidly inhibit the newly arrived NK cells, causing their killing capacity to decline sharply. This is precisely why NK cell therapy used alone often produces limited results. Effective strategies typically combine NK cell infusion with local radiotherapy, chemotherapy, or immune checkpoint inhibitors to first improve the tumor microenvironment.
③ An adjunctive, not a primary, therapy
Perhaps the most important reality to face is that NK cell therapy is an adoptive cell therapy and, at this stage, is not a curative intervention. It cannot replace surgical resection, curative radiotherapy, or the core role of targeted therapy. For advanced, large solid tumors, NK cells alone are unlikely to achieve complete clearance. Its clinical role is adjunctive: postoperative adjuvant therapy to eliminate microscopic residual disease and prevent recurrence; second- or third-line salvage therapy after standard treatments have failed; and as a booster in combination regimens to amplify overall efficacy.
In summary, NK cell therapy is designed to clear circulating tumor cells and residual microscopic lesions that surgery, radiotherapy, and chemotherapy cannot easily reach. It also helps “awaken” the patient’s own dormant T-cell immune system through signals released by killed cancer cells. But expecting NK cells alone to eliminate large, advanced tumors mistakes an “adjunctive” tool for a “primary” one — a misconception that is itself dangerous.
Indications and Patient Selection
The approved indications for this therapy are eight solid tumor types: lung cancer, breast cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, ovarian cancer, and prostate cancer. There is no restriction on tumor stage, meaning the therapy may be considered for patients at early-to-mid stages seeking to reduce postoperative recurrence risk, as well as for patients with advanced disease aiming to improve overall treatment outcomes and extend survival.
However, the therapy requires combination with PD-1 inhibitors. Eligible patients must have PD-L1 testing positive, or microsatellite instability-high (MSI-H), or mismatch repair deficiency (dMMR).
Key inclusion criteria include: age ≥ 18 years; diagnosis of one of the eight specified solid tumor types; previous treatment with immune checkpoint inhibitor-containing regimens with clinical indication for continued ICI maintenance therapy; ECOG performance status 0–2; Child-Pugh score ≤ 7; life expectancy ≥ 3 months; adequate hematologic, hepatic, and renal function; and negative screening for hepatitis B, syphilis, HIV-1/2, and hepatitis C.
Exclusion criteria include: current use of immunosuppressive medications or long-term immunosuppressant use after organ transplantation; active acute illness or active bleeding; severe hepatic or renal dysfunction; refractory or persistent epilepsy; pregnancy or breastfeeding; and known allergies to aminoglycosides, bacitracin, human serum albumin, or radiocontrast media.
Treatment Pathway and Practical Considerations
The treatment pathway follows a structured sequence:
- Initial consultation and eligibility assessment – Patients undergo evaluation at the designated hospital to confirm suitability.
- Blood collection – Peripheral blood is drawn to obtain autologous NK cells.
- Cell manufacturing – NK cells are isolated, expanded, and activated in a GMP-compliant laboratory. This process takes approximately two weeks.
- Reinfusion – The expanded NK cells are administered via intravenous infusion (approximately 100 mL) over about one hour. Each course consists of 3 to 6 infusions, administered once every two weeks.
The procedure is outpatient-based and generally well-tolerated. Most patients experience no significant side effects. Transient low-grade fever may occur in some cases, typically resolving within hours.
Cost Structure
The approved price for autologous NK cell adjuvant immunotherapy for solid tumors is ¥49,800 per infusion. A full course comprises 3 to 6 infusions, bringing the total cost to ¥149,400 for a 3-infusion course or ¥298,800 for a 6-infusion course.
These figures cover the cell manufacturing, medical procedures, and hospital services. They do not include travel, accommodation, or ancillary medications. Patients should also consider the cost of concurrent PD-1 inhibitor therapy, which is prescribed and administered separately.
Regulatory and Safety Context
This therapy operates under formal approval from the Lecheng Medical Products and Administration Bureau, as part of the pilot zone’s regulatory framework for biomedical innovation. The program is conducted at West China Lecheng Hospital—a tertiary hospital affiliated with Sichuan University’s West China Hospital system—and at Lecheng Maisel International Hospital. This institutional backing ensures adherence to established clinical protocols and quality standards.
The safety profile of autologous NK cell therapy is supported by extensive clinical experience. Because the cells are derived from the patient’s own blood, the risk of immune rejection is minimal. To date, no severe adverse events directly attributable to the NK cell infusion have been reported in the program.
A Practical Perspective from a Service Provider
Having assisted patients through the evaluation and treatment process at Lecheng, I can share that the most common questions relate to eligibility, expected outcomes, and the coordination of care. Patients appreciate the clarity of the protocol and the availability of detailed informed consent materials. The hospital provides comprehensive pre-treatment counseling, and our service team assists with travel arrangements, accommodation, and appointment scheduling for patients coming from other provinces.
It is important to emphasize that this is an adjunctive therapy—it is not intended to replace conventional treatments such as surgery, radiotherapy, or chemotherapy. Rather, it is designed to complement these modalities by addressing residual micrometastases and reducing the risk of recurrence. The decision to pursue NK cell therapy should be made in consultation with the patient’s primary oncologist, taking into account the individual’s tumor type, stage, prior treatment history, and overall clinical status.
In summary, the autologous NK cell therapy program at Lecheng represents a regulated, evidence-based adjunctive option for patients with certain solid tumors. While longer-term data continue to accrue, the current clinical evidence and regulatory framework provide a solid foundation for informed decision-making.
“NK cell therapy does not replace standard oncology treatments—it enhances them, by mobilizing the patient’s own immune system to clear residual disease.”
Disclosure: The author works for a medical tourism service provider that assists patients in accessing treatments at Lecheng. This article is intended for informational purposes and does not constitute medical advice. Patients are strongly encouraged to consult their own physicians before making any treatment decisions.
References: All clinical and program information is derived from official materials from West China Lecheng Hospital, Lecheng Maisel International Hospital, and the Lecheng Medical Products and Administration Bureau, as well as published analyses of NK cell therapy limitations.
